Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?

被引：18
|
作者：
Shichijo, Takafumi [1 ,2 ]
Fuji, Shigeo [3 ]
Nagler, Arnon [4 ]
Bazarbachi, Abdulhamid [5 ,6 ,7 ]
Mohty, Mohamad [5 ,6 ,7 ]
Savani, Bipin N. [7 ,8 ]
机构：
[1] Kumamoto Univ, Fac Life Sci, Dept Hematol Rheumatol & Infect Dis, Kumamoto, Japan
[2] Kyoto Univ, Inst Frontier Life & Med Sci, Lab Virus Control, Kyoto, Japan
[3] Osaka Int Canc Inst, Dept Hematol, Osaka, Japan
[4] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel
[5] St Antoine Hosp, INSERM, UMR 938, Serv Hematol Clin & Therapie Cellulaire, Paris, France
[6] St Antoine Hosp, INSERM, UMR 938, EBMT Paris Study Off, Paris, France
[7] Sorbonne Univ, Paris, France
[8] Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Nashville, TN USA
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 03期
关键词：
LEUKEMIA WORKING PARTY; T-LYMPHOCYTE GLOBULIN; BONE-MARROW-TRANSPLANTATION; MATCHED UNRELATED DONORS; ACUTE MYELOID-LEUKEMIA; INTENSITY CONDITIONING REGIMEN; CONSENSUS DEVELOPMENT PROJECT; SEVERE APLASTIC-ANEMIA; BLOOD STEM-CELLS; TERM-FOLLOW-UP;
D O I：
10.1038/s41409-019-0643-9
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
The efficacy of anti-thymocyte globulin (ATG) as prophylaxis for graft-versus-host disease (GVHD) has been investigated by many clinical studies over the past decade, including some randomized controlled trials. Intriguingly, although ATG is commonly used as prophylaxis for GVHD, there is still controversy about the optimal dose of ATG for prophylaxis of GVHD after allogeneic hematopoietic cell transplantation (allo-HCT). Indeed, the dose and formulation of ATG, as well as the degree of clinical benefit, has varied among studies, which makes it difficult to fully determine the clinical benefit of ATG. The aim of this review is to summarize the information regarding the optimal ATG dose of each formulation according to stem cell source, and to discuss how best to determine the personalized optimal dose of ATG in each allo-HCT recipient.
引用
收藏
页码：505 / 522
页数：18
相关论文
共 50 条
  • [41] Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
    van Lier, Yannouck F.
    Vos, Jael
    Blom, Bianca
    Hazenberg, Mette D.
    [J]. GUT MICROBES, 2023, 15 (01)
  • [42] Role of Defibrotide in the Prevention of Murine Model Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
    Palaniyandi, Senthilnathan
    Kumari, Reena
    Strattan, Ethan
    Huang, Timothy
    Kohler, Katharina
    Du, Jing
    Jabbour, Nashwan
    Kesler, Melissa
    Hildebrandt, Gerhard C.
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (10): : 608.e1 - 608.e9
  • [43] Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
    Toubai, Tomomi
    Paczesny, Sophie
    Shono, Yusuke
    Tanaka, Junji
    Lowler, Kathleen P.
    Malter, Chelsea T.
    Kasai, Masaharu
    Imamura, Masahiro
    [J]. CURRENT STEM CELL RESEARCH & THERAPY, 2009, 4 (04) : 252 - 259
  • [44] Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation
    Kuriyama, Kodai
    Fuji, Shigeo
    Inamoto, Yoshihiro
    Tajima, Kinuko
    Tanaka, Takashi
    Inoue, Yoshitaka
    Ito, Reiko
    Hayashi, Yoshiki
    Ito, Ayumu
    Kurosawa, Saiko
    Kim, Sung-Won
    Yamashita, Takuya
    Fukuda, Takahiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (04) : 453 - 460
  • [45] Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation - a systematic meta-analysis
    Theurich, S.
    Fischmann, H.
    Shimabukuro-Vornhagen, A.
    Chemnitz, J.
    Holtick, U.
    Scheid, C.
    Skoetz, N.
    von Bergwelt-Baildon, M.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 : S11 - S11
  • [46] Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation
    Kodai Kuriyama
    Shigeo Fuji
    Yoshihiro Inamoto
    Kinuko Tajima
    Takashi Tanaka
    Yoshitaka Inoue
    Reiko Ito
    Yoshiki Hayashi
    Ayumu Ito
    Saiko Kurosawa
    Sung-Won Kim
    Takuya Yamashita
    Takahiro Fukuda
    [J]. International Journal of Hematology, 2016, 103 : 453 - 460
  • [47] The beneficial impact of incorporation of low-dose anti-thymocyte globulin (rabbit) 5mg/kg to standard graft-versus-host disease prophylaxis in matched or mismatched unrelated allogeneic stem cell transplantation
    Batsis, I.
    Mallouri, D.
    Bousiou, Z.
    Constantinou, V.
    Apostolou, C.
    Tsirou, K.
    Kaloyannidis, P.
    Smias, C.
    Yannaki, E.
    Fylaktou, A.
    Anagnostopoulos, A.
    Sakellari, I.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : S178 - S179
  • [48] Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation
    Flaman, Flavia
    Zieroth, Shelley
    Rao, Vivek
    Ross, Heather
    Delgado, Diego H.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (11): : 1358 - 1362
  • [49] High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation
    Lim, Andrew Boon Ming
    Storek, Jan
    Beligaswatte, Ashanka
    Collins, Marnie
    Mason, Kate
    Li, Emily Peizhen
    Chaudhry, Ahsan
    Russell, James A.
    Daly, Andrew
    Szer, Jeffrey
    Lewis, Ian
    Ritchie, David Stuart
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S334 - S334
  • [50] TREATMENT OF ACUTE GRAFT VERSUS HOST-DISEASE WITH ANTI-THYMOCYTE GLOBULIN
    GRATWOHL, AA
    HERZIG, GP
    GRAW, RG
    RAFI, M
    [J]. EXPERIMENTAL HEMATOLOGY, 1978, 6 : 43 - 43
12345